Please assess the completion status of the following clinical trial:

Trial Title: BАbykids Spray In Common Cold

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1. Male/Female subjects \>2 and ≤6-year-old~* 2. Acute infectious rhinitis/rhinosinusitis for ≤48h before trial entry~* 3. Patient presenting with fever ≥ 37.5 °C at screening~* 4. Subjects with nasal congestion (blocked / stuffy nose) rated at least as moderate on the Acute Rhinitis Symptoms Severity Questionnaire, based on evaluation by the investigator~* 5. Subjects showing at least moderate grade for at least one of the following additional signs of acute rhinitis: runny nose, nasal crust (dry mucus), sneezing and cough~* 6. Written consent obtained from parent/legal guardians~Exclusion Criteria:~* 1. Known hypersensitivity/allergy to any component of the test device~* 2. Medical history that is considered by the investigator as a reason for non-inclusion,~* 3. Severe nasal septum deviation or other condition that could cause nasal obstruction such as the presence of nasal polyps~* 4. History of nasal or sinus surgery that in the opinion of the investigator may influence symptom scores~* 5. Antibiotic intake within 2 weeks before screening~* 6. Systemic corticosteroids within 4 weeks before screening~* 7. Chronic decongestant use~* 8. Recent (within the previous 2 days) intake of a common cold medicine that in the opinion of the investigator may influence ARSSQ score at screening (NSAID, nasal decongestants, cough medicines)

- Gender: ALL
- Minimum Age: 25 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- Healsea Babykids (Type: EXPERIMENTAL): Healsea® Babykids, nasal spray indistinguishable from the comparator. Subjects have to spray 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes ) up to 10 days (20 intakes ).
- Placebo (Type: PLACEBO_COMPARATOR): The comparator is a saline isotonic nasal spray considered as inert Placebo i.e., neutral for the nasal mucosa.~Subjects have to spray 2 puffs in each nostril 2 times per day with a minimum of 7-day-treatment period (14 intakes ) up to 10 days (20 intakes ).

Based on this trial design, predict the completion outcome and termination type (if applicable).